To print this article, all you need is to be registered or login on Mondaq.com.
On January 14, 2021, in a decision that may prompt the Office
for Civil Rights (OCR) of the Department of Health and Human
Services to realign its enforcement approach, a three-member panel
for the Fifth Circuit unanimously vacated a $4.3 million penalty
that OCR imposed on the University of Texas MD Anderson Cancer
Center (MD Anderson) for alleged violations of the privacy and
security regulations implementing the Health Insurance Portability
and Accountability Act (HIPAA) and the Health Information
Technology for Economic and Clinical Health Act. The case arose
4D pharma presents update on oncology program
4D pharma presents update on oncology program
Enrollment progressing well for both expanded Part B of MRx0518 and Keytruda combination study, and pancreatic cancer study
Further analysis of biomarker data in ongoing MRx0518 neoadjuvant monotherapy study
Leeds, UK – February 3, 2021 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.
“4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. This clinical and development